Anteris Technologies (AVR) announced the first patients have been enrolled and successfully treated in the DurAVR Transcatheter Heart Valve global pivotal trial for patients with severe calcific aortic stenosis. The trial builds on Anteris’ existing clinical data set of 130 patients successfully treated with the DurAVR THV, including de novo aortic stenosis cases, valve-in-valve patients and complex anatomies such as bicuspid aortic valve patients. Anteris aims to drive the global PARADIGM Trial through the addition of further countries and sites in the near term, with planned expansion across the U.S., Europe and Canada.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVR:
- Anteris Technologies Raises $11.5M in Stock Offering
- Anteris Technologies to present on one-year outcomes for DurAVR THV
- Anteris Technologies Announces Share Sale Agreement
- Anteris Technologies Prepares for Annual Stockholder Meeting
- Anteris Technologies Gains European Clearance for Heart Valve Trial